Leveraging Integrated & Advanced Technologies for Successful Cell Line Development
Successful cell line development is heavily dependent upon balancing time and resources with acquiring high quality data for informed decisions. Each stage of the cell line development workflow has challenges and there is a real need for advanced strategies and intelligent use of innovative solutions.
This webinar focuses on early-stage cell line development with tools that are tailored for high-throughput screening, enabling reliable identification of robust, scalable, and high-titer clones. The CellCelector, iQue®, Octet® and Ambr® 15 CC platforms are perfectly designed to seamlessly work together to streamline the early cell line development workflow, enabling data-driven decisions and reducing risk during later stages of biologic development.
- The early cell line development workflow and the bottlenecks associated with the various stages
- How Sartorius instruments are suited to high-throughput demands and where they fit into the cell line development workflow
- Establishing a strategy for a simplified approach to cell line development
Meet Our Experts:
Daryl Cole, PhD
Applications Scientist, Sartorius
Daryl Cole earned a PhD in Molecular Oncology from King’s College London in 2008 and joined Sartorius in 2021 as a Scientist in the Bio Applications Team, working with the Incucyte, Octet, and iQue but with a focus on iQue applications development. He has over 10 years of experience in a range of scientific fields from cancer research to organoid and stem cell development.
Fern Slingsby, PhD
Product Specialist, Sartorius
Fern Slingsby has been working for Sartorius since 2018. She obtained her undergraduate degree in Molecular Biology from Queen Mary, University of London, and her PhD from the Medical Research Council (UK) / University of Edinburgh.
Fern has over 18 years of experience in recombinant protein production and upstream development. Her background includes eight years as a project leader and program manager of biopharmaceutical cGMP manufacture from pre-clinical to clinical phase I, II and III.
At Sartorius, Fern supports customers through incorporating high-throughput technologies into cell line and process development, focusing on the Ambr® technology and integrated platforms.